Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats

Figure 3 Effects of gypenosides on blood lipid and glucose levels. A: Oral glucose tolerance: the blood glucose levels were measured before the glucose challenge; B: The area under the curve (AUC _{0-120 min}) after 30, 60, 90 or 120 min challenge was calculated and analyzed. (I) normal control, (II) model, (III) gypenosides (GPs) (200 mg/kg) + HFSD, (IV) GPs (400 mg/kg) + HFSD, (V) GPs (800 mg/kg) + HFSD. The values are expressed as mean ± SD in each group. ^aP < 0.05 vs normal control, ^cP < 0.05 vs model; n = 12.